Vaccinex presents at Jefferies conference on KEYNOTE-B84 study; no new data disclosed

VACCINEX, INC.

Presented at Jefferies Healthcare Conference on June 10, 2022 at 10:30 a.m. ET.
Presentation covered the KEYNOTE-B84 study of pepinemab (anti-SEMA4D) in HNSCC.
Filing does not include any new clinical data or financial results.
Corporate slide deck furnished as Exhibit 99.1, available on company website.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.